PI3K and PARP Inhibitors in HR+ Metastatic Breast Cancer
15 vistas
• 07/03/23
0
0
Empotrar
administrator
Suscriptores
Joyce A. O’Shaughnessy, MD, and Andrew D. Seidman, MD, evaluate treatment options outside of CDK4/6 inhibition, such as PI3-kinase or poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors, for patients with hormone-receptor positive metastatic breast cancer.
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios